116 related articles for article (PubMed ID: 38899842)
1. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel RA; Mushlin AI; Zheng X; Mao J; Carlos R; Brown RS; Ibrahim S; Fortune BE; Talenfeld AD; Madoff DC; Johnson MS; Sedrakyan A
AJR Am J Roentgenol; 2024 Jun; ():. PubMed ID: 38899842
[No Abstract] [Full Text] [Related]
2. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
[TBL] [Abstract][Full Text] [Related]
3. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma.
Skill NJ; Butler J; O'Brien DC; Kays JK; Kubal CA; Liangpunsakul S; Ninad N; Maluccio MA
Transplant Proc; 2019; 51(6):1907-1912. PubMed ID: 31399174
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
5. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
[TBL] [Abstract][Full Text] [Related]
6. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
7. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
8. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
9. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.
Uhlig J; Sellers CM; Stein SM; Kim HS
Eur Radiol; 2019 May; 29(5):2679-2689. PubMed ID: 30560364
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort.
Charalel RA; Mushlin AI; Li D; Mao J; Ibrahim S; Carlos RC; Kwan SW; Fortune B; Talenfeld AD; Brown RS; Madoff DC; Johnson MS; Sedrakyan A
J Am Coll Radiol; 2022 Nov; 19(11):1213-1223. PubMed ID: 36208842
[TBL] [Abstract][Full Text] [Related]
11. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effectiveness of surgical resection and ablation for the treatment of early-stage hepatocellular carcinoma: A retrospective cohort study.
Yang B; Xi X; Yu H; Jiang H; Liang Z; Smayi A; Wu B; Yang Y
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2030. PubMed ID: 38488487
[TBL] [Abstract][Full Text] [Related]
13. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
[TBL] [Abstract][Full Text] [Related]
14. Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies.
Hu L; Lin J; Wang A; Shi X; Qiao Y
World J Surg Oncol; 2024 Feb; 22(1):56. PubMed ID: 38369480
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
[No Abstract] [Full Text] [Related]
17. A nationwide propensity score analysis comparing ablation and resection for hepatocellular carcinoma.
Rasic G; de Geus SWL; Beaulieu-Jones B; Kasumova GG; Kent TS; Ng SC; McAneny D; Tseng JF; Sachs TE
J Surg Oncol; 2023 Jun; 127(7):1125-1134. PubMed ID: 36905338
[TBL] [Abstract][Full Text] [Related]
18. Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study.
Charalel RA; Mushlin AI; Zheng X; Mao J; Carlos R; Brown RS; Fortune BE; Talenfeld AD; Madoff DC; Ibrahim S; Johnson MS; Sedrakyan A
J Am Coll Radiol; 2024 Feb; 21(2):295-308. PubMed ID: 37922972
[TBL] [Abstract][Full Text] [Related]
19. Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study.
Ruzzenente A; Guglielmi A; Sandri M; Campagnaro T; Valdegamberi A; Conci S; Bagante F; Turcato G; D'Onofrio M; Iacono C
J Gastrointest Surg; 2012 Feb; 16(2):301-11; discussion 311. PubMed ID: 22095524
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
